CJC-1295 + Ipamorelin: Research Overview

CJC-1295 + Ipamorelin is a paired research blend combining a growth hormone-releasing hormone (GHRH) analog with a growth hormone secretagogue receptor agonist — the two receptor inputs of the pituitary's growth-hormone-release machinery. The pairing is a standard design in growth-hormone-axis research because the compounds act on different receptors in the same pathway, letting researchers study synergistic pulsatility rather than single-receptor stimulation. This overview covers both components, the synergy rationale, the key literature, and how the blend is supplied.

Component 1: CJC-1295 (GHRH analog)

CJC-1295 is a synthetic analog of GHRH(1-29) — the shortest fully active fragment of the native 44-amino-acid hormone — carrying four amino-acid substitutions (including D-Ala at position 2) that protect it from rapid cleavage by the enzyme DPP-4. Native GHRH(1-29) has a half-life of minutes in experimental systems; the tetrasubstituted analog was engineered to solve that problem.

The pivotal published study (Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism, 2006) reported dose-dependent, sustained elevations of GH and IGF-1 following single administrations in healthy volunteers — evidence that the stabilized analog engages the GHRH receptor with prolonged effect. Research distinguishes two forms: versions conjugated to a Drug Affinity Complex (DAC) that binds albumin for very long duration, and the unconjugated tetrasubstituted analog (often called modified GRF 1-29) studied for shorter, more physiological pulses.

Component 2: Ipamorelin (selective secretagogue)

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) agonist of the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor. Its defining research property is selectivity. The characterization literature (including Raun and colleagues, European Journal of Endocrinology, 1998) described ipamorelin as releasing GH in models without the off-target endocrine effects seen with earlier secretagogues such as GHRP-6 or hexarelin — notably without significant ACTH, cortisol, or prolactin changes at effective research doses. That clean profile made ipamorelin the reference GHRP in modern GH-axis research.

Why researchers pair them

The GHRH receptor and the ghrelin receptor use different second-messenger systems (Gs/cAMP and Gq, respectively) and converge on the same somatotroph cells. Published preclinical work describes amplified, more physiological GH pulses when both receptor systems are engaged together — the two compounds address different bottlenecks in the release machinery. The pairing also lets researchers dissect which effects track with which receptor, something single-compound designs cannot do.

Key published findings

• CJC-1295 pharmacology (JCEM, 2006): randomized, double-blind, placebo-controlled work reported dose-dependent GH and IGF-1 elevations with an extended duration profile, establishing the stabilized analog's research utility.
• Ipamorelin selectivity (1998 onward): characterization studies described potent GH release with minimal cortisol/prolactin effect in models — the selectivity that distinguishes it from first-generation secretagogues.
• Synergy literature: preclinical research on GHRH + GHRP combinations describes synergistic (greater than additive) GH-release responses, the mechanistic basis of the pairing.
• Pulsatility research: studies using GHRH analogs examine how stabilized stimulation interacts with the natural pulsatile rhythm, contrasting with the continuous elevation produced by exogenous GH in models.

Context among related compounds

This pairing complements tesamorelin research: tesamorelin is the deeply characterized pure GHRH analog, while CJC-1295 + Ipamorelin adds the ghrelin-receptor dimension. Together they bracket modern GH-axis research design — single-input physiological stimulation versus dual-input synergy.

What researchers examine

Research questions include receptor cross-talk in somatotroph models, pulse-waveform analysis, IGF-1 endpoint tracking, analog-stability engineering (DPP-4 resistance, albumin binding), and secretagogue selectivity profiling. The blend is supplied as a single lyophilized preparation for laboratory convenience in multi-pathway designs.

Frequently asked research questions

Why are CJC-1295 and ipamorelin studied together?

They act on different receptors in the same growth-hormone pathway (GHRH receptor and ghrelin/GHS receptor). Research models describe synergistic pulsatility when both are engaged — the rationale for the pairing.

What makes ipamorelin notable among secretagogues?

Published characterization work describes unusual selectivity: GH-axis activity with minimal effect on cortisol, ACTH, or prolactin markers in research models, unlike earlier compounds in its class.

What is the difference between CJC-1295 with and without DAC?

The DAC (Drug Affinity Complex) version binds albumin for very long duration in experimental systems; the unconjugated stabilized analog is studied for shorter, more physiological stimulation windows. Research literature distinguishes the two forms explicitly.

Is this blend an approved treatment?

No. It is supplied strictly as laboratory research material for in-vitro use and is not for human or veterinary use.

How is it supplied and verified?

Lyophilized powder in sealed vials, with each component purity-verified at ≥99% by independent third-party HPLC analysis.

What does "no DAC" mean in research listings?

DAC (Drug Affinity Complex) is a reactive group that conjugates CJC-1295 to albumin for very long duration. "No DAC" versions are the stabilized tetrasubstituted GHRH(1-29) analog without that conjugation — studied for shorter, more physiological stimulation windows. The research literature treats them as distinct tools.

How should the research material be stored?

Lyophilized vials: frozen at -20°C or below for long-term storage, protected from light and moisture. After reconstitution under sterile laboratory conditions, keep refrigerated at 2–8°C and use within the protocol's validated window.

How the evidence base reads

The pairing rests on peer-reviewed component literature: a randomized placebo-controlled human pharmacology publication for CJC-1295 (JCEM, 2006), formal characterization studies for ipamorelin (1998 onward), and a preclinical synergy literature for GHRH + GHRP combinations. The blend itself is a research preparation; component findings describe the individual compounds in their studied contexts.

Laboratory handling and stability

For long-term research storage, keep lyophilized vials frozen at -20°C or below, protected from light and moisture; short-term handling at 2–8°C is standard. Reconstitution should be performed only under sterile laboratory conditions with the laboratory-grade solvent specified by the research protocol, and reconstituted material should be kept cold, protected from light, and used within the validated window of the protocol. Record vial lot numbers and retain the certificate of analysis with study records — traceability is a baseline requirement for reproducible work.

Related research in this library

Tesamorelin · Retatrutide · KLOW Blend

Form, handling, and verification

CJC-1295 + Ipamorelin is supplied as a lyophilized (freeze-dried) powder in sealed vials, with identity and purity verified at ≥99% by independent third-party HPLC analysis. Lyophilized material should be stored in a cool, dry environment away from light and handled per standard laboratory protocol with appropriate protective equipment.

View CJC-1295 + Ipamorelin research material →

Research Use Only. All materials referenced are supplied strictly for qualified in-vitro laboratory research. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use.